Amylyx Pharmaceuticals has been granted a patent for a method to treat ALS symptoms. The method involves administering Taurursodiol and sodium phenylbutyrate to patients who have received a first dosage of a BSEP inhibitor, with the second dosage being lower. The treatment aims to improve patient response. GlobalData’s report on Amylyx Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Amylyx Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Amylyx Pharmaceuticals's grant share as of April 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11938142B2) discloses a method for administering Taurursodiol (TURSO) and sodium phenylbutyrate to individuals with Amyotrophic Lateral Sclerosis (ALS) who have previously received cyclosporine. The method involves administering a specific composition of TURSO and sodium phenylbutyrate, determining levels of serum transaminases and/or bilirubin in biological samples, and adjusting the dosage of cyclosporine based on the results. The patent specifies that the onset of ALS symptoms should be more than 24 months, and the initial dosage of cyclosporine should range from 0.5 to 15 mg/kg/day.
Furthermore, the patent includes additional steps such as determining a second level of serum transaminases and/or bilirubin in a second biological sample, with the expectation that the levels would be lower than the first. The method allows for flexibility in the administration of TURSO and sodium phenylbutyrate, with options for once or twice daily dosages. The composition can be administered orally or through a feeding tube to individuals diagnosed with ALS or suspected of having the condition. Overall, the patent outlines a comprehensive method for managing ALS symptoms in individuals who have previously received cyclosporine, offering potential advancements in the treatment of this debilitating disease.
To know more about GlobalData’s detailed insights on Amylyx Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.